Background
==========

Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin agonists (^90^Y- or ^177^Lu-DOTATOC/-TATE) is routinely used for advanced neuroendocrine tumours (NET) or other entities such as meningioma that overexpress somatostatin receptor subtype II (SSTR II) \[[@B1]\]-\[[@B6]\]. Whereas the high-energy emitter ^90^Y was first considered more effective, especially in bulky disease \[[@B7]\], some studies reported on higher incidence and severity of side effects like myelosuppression and especially renal toxicity \[[@B4]\],\[[@B8]\]. Since the radiopeptide is reabsorbed at the proximal tubule, subsequent retention may lead to excessive radiation doses and renal failure. In order to prevent significant renal radiopeptide retention, positively charged amino acids (AA) such as [l]{.smallcaps}-arginine and [l]{.smallcaps}-lysine have been introduced and are used in different protocols for 1 or 2 days \[[@B9]\].

The AA bind to the tubular megalin/cubulin system (which serves as a scavenger system for the reabsorption of AA) and compete with the radiopeptide for reabsorption \[[@B10]\],\[[@B11]\]. The co-administration leads to a significant reduction in the renal absorbed dose \[[@B6]\],\[[@B12]\]. However, side effects like nausea, vomiting and hyperkalaemia have been described \[[@B13]\],\[[@B14]\]. Several authors have reported on the influence of the composition and amount of AA administered on serum potassium levels \[[@B11]\],\[[@B13]\].

The aim of this study was to compare incidence and severity of post-therapeutic hyperkalaemia (\>5.0 mmol/l) in patients undergoing PRRT with two different AA infusion regimens administering 50 or 75 g of mixed [l]{.smallcaps}-arginine and [l]{.smallcaps}-lysine.

Methods
=======

Study design and characterization of the patient cohort
-------------------------------------------------------

Twenty-two consecutive patients (13 males, 9 females) referred for PRRT received 75 g of [l]{.smallcaps}-arginine and [l]{.smallcaps}-lysine for the first cycle and 50 g of AA for the second cycle, respectively. Mean age was 58?±?14 years (range, 24 to 82 years). The general inclusion and exclusion criteria as defined by *The joint IAEA, EANM and SNMMI practical guidance* were applied \[[@B9]\]. Table [1](#T1){ref-type="table"} gives an overview on patients\' characteristics.

###### 

Main baseline features of the patients enrolled in the study

  **Patient**   **Age**   **Sex**   **Primary tumour**         **Metastases**              **Previous therapy**
  ------------- --------- --------- -------------------------- --------------------------- -------------------------------------
  1             76        M         Ileum NET                  Liver                       Octreotide, interferon alfa
  2             62        M         Meningioma                 None                        None
  3             61        M         Pancreatic NET             Local vessel infiltration   Stenting
  4             82        F         Pancreatic NET             Liver, bone                 Surgery
  5             50        M         Rectal NET                 Bone                        Surgery
  6             67        F         Liver NET                  LN, muscle, brain           Surgery
  7             69        M         Small bowel NET            Liver, lung, LN             None
  8             50        F         Pancreatic NET             Liver, LN                   Octreotide, everolimus, lanreotide
  9             49        M         Small cell lung cancer     LN                          CTx
  10            73        F         Pancreatic NET             Bone, liver                 Surgery
  11            58        F         Ileum NET                  Liver, LN                   Surgery, octreotide, thermoablation
  12            57        F         Carcinoid                  Lung, bone                  Surgery, RCTx
  13            31        F         Medullary thyroid cancer   Lung, LN, bone              Surgery, CTx
  14            24        M         Ileum NET                  Liver                       Surgery, TACE, octreotide
  15            66        M         Thymus NET                 Bone, lung, LN              None
  16            60        F         Meningioma                 None                        Surgery
  17            34        M         Paraganglioma              Bone                        Surgery, RTx
  18            61        M         Small bowel NET            Liver, LN                   Surgery, octreotide
  19            55        M         Pancreatic NET             Liver, LN                   CTx
  20            63        M         Pancreatic NET             LN, liver, bone             Surgery
  21            68        F         Small bowel NET            Liver, LN                   Surgery
  22            54        M         Cerebral NET               Bone                        CTx

*M* male, *F* female, *NET* neuroendocrine tumour, *LN* lymph nodes, *CTx* chemotherapy, *RCTx* radiochemotherapy, *TACE* transcatheter arterial chemoembolization, *RTx* radiotherapy.

All patients gave written informed consent to the implementation of standard-of-care PRRT. As this study comprised exclusively retrospective analysis of routinely acquired data, our institutional review board (ethics committee of the Medical Faculty of the University of Würzburg) waived the requirement for additional approval. In October 2013, the amount of AA routinely administered was reduced from 75 to 50 g to comply with the latest *joint IAEA, EANM and SNMMI practical guidance*\[[@B9]\].

All patients were observed for two consecutive treatment cycles. Admission occurred one day prior to PRRT itself to allow for adequate hydration. During the first treatment cycle, 1,500 ml of standard solution containing 37.5 g of arginine hydrochloride and 37.5 g of lysine hydrochloride (pH, 7.0) was administered within 4 h (0.5 to 1 h prior to PRRT and for a total of 3 to 3.5 h after therapy; infusion rate, 375 ml/h). For the second cycle, 25 g of each AA in a total of 2,000 ml saline was infused within the same time period (0.5 to 1 h prior to PRRT and for a total of 3 to 3.5 h after therapy; infusion rate, 500 ml/h) according to the most recent practical guidance \[[@B9]\]. The AA solutions were produced in-house according to GMP criteria.

For the first treatment cycle, a mean of 7.5?±?0.7 GBq of ^177^Lu-DOTATATE in 12 ml of normal saline was intravenously infused over 30 min; for the second cycle, 7.6?±?0.3 GBq of ^177^Lu-DOTATOC was administered.

Preparation of 177Lu-DOTATATE/-TOC
----------------------------------

^177^Lu-DOTATATE/-TOC was prepared using a radiotracer synthesis module (Scintomics, Fürstenfeldbruck, Germany) with minor modifications as described before \[[@B15]\]. Briefly, a solution of 200 ?g DOTATATE/-TOC-acetate (ABX, Radeberg, Germany) and 7 mg gentisic acid in 600 ?l sodium acetate buffer (pH?=?4 to 5) was added to a solution of 8 GBq ^177^LuCl~3~ in 0.04 M hydrochloric acid (Isotope Technologies Garching, Garching, Germany) and heated for 30 min at 95°C. The product was diluted with saline and passed through a sterile filter (0.22 ?m) into a sterile vial. Radiochemical purity was determined by gradient high-performance liquid chromatography and thin layer chromatography. Additionally, the product was also tested for pH, sterility and endotoxins.

Pre- and post-therapeutic blood samples
---------------------------------------

Blood samples of each patient were drawn to assess standard blood values one day before PRRT and 4 and 24 h after AA infusion. Serum levels of potassium and other parameters (glomerular filtration rate \[GFR\], creatinine, blood urea nitrogen \[BUN\], phosphate, chloride, lactate dehydrogenase \[LDH\]) were compared. Whereas hyperkalaemia is routinely defined by our laboratories as serum K^+^ levels \>5.0 mmol/l, severe hyperkalaemia was arbitrarily defined as serum values ?6.0 mmol. Serum potassium levels were measured by indirect ion-sensitive electrode (ISE) (Cobas 8000 system, Roche Diagnostics, Mannheim, Germany). All samples were screened for haemolysis. Absorbances of the diluted serum samples (dilution 1:26) were measured at 570 nm (primary wavelength) and at 600 nm (secondary wavelength), and the haemolysis indices were calculated according to the manufacturer\'s instruction. Serum samples with haemolysis indices above 90 (equaling 90 mg/dl of free haemoglobin) were considered to be haemolytic and excluded from further evaluation (\<5%).

Analysis and statistics
-----------------------

Statistical analyses were performed using PASW Statistics software (version 22.0; SPSS, Inc. Chicago, IL, USA). Quantitative values were expressed as mean?±?standard deviation and range as appropriate. Comparisons of related metric measurements were performed using Wilcoxon signed rank test.

Results
=======

Post-PRRT clinical symptoms
---------------------------

After completion of PRRT, three patients of the 75 g group presented with palpitations, chest pain and/or general discomfort. Evaluation of ECG revealed flattened P waves and high peaked T waves. Two of those three patients also became symptomatic after administration of 50 g AA, whereas the remaining tolerated this regimen without discomfort. In all symptomatic cases, serum potassium levels were ?6.1 mmol/l with peak values of 7.9 mmol/l and required prompt intervention by infusion of 20 IU insulin with 20% glucose in 500 ml saline.

Besides, other side effects being not related to hyperkalaemia were observed in both patient cohorts (e.g. nausea, vomiting and decrease of kidney function).

At baseline, mean K^+^ levels were 4.4?±?0.4 mmol/l (75 g) and 4.3?±?0.4 mmol/l (50 g), respectively. At 4 h, 20/22 subjects (91%) in both groups had serum potassium levels ?5.0 mmol/l with a mean of 5.8?±?0.7 mmol/l (75 g) and 5.7?±?0.8 mmol/l (50 g), respectively. Increases in K^+^ levels were comparable (25% for 75 g, *p*?\<?0.001 and 24% for 50 g AA, *p*?\<?0.001).

In both groups, severe hyperkalaemia defined as K^+^ \>6.0 mmol/l was observed in 8/22 (36%) patients. After 24 h, K^+^ levels almost returned to baseline (mean, 4.5?±?0.4 mmol/l (75 g AA) vs. mean, 4.6?±?0.4 (50 g AA)) (Figure [1](#F1){ref-type="fig"}). No significant differences between both AA protocols were found at any time point.

![**Serum K**^**+**^**levels.** Serum K^+^ levels at baseline, 4 h post-infusion and 24 h post-infusion (mmol/l; 50 g amino acid vs. 75 g amino acid). \*\*4 h in comparison to baseline (50 g/75 g): *p*?\<?0.001; ^\#^4 h in comparison to 24 h (50 g/75 g): *p*?\<?0.001; \*24 h in comparison to baseline (50 g): *p*?\<?0.05. Empty bars show serum K^+^ concentrations after administration of 50 g AA, and full bars show serum K^+^ concentrations after administration of 75 g AA.](s13550-014-0046-2-1){#F1}

At 4 h post-infusion, all other parameters investigated showed only minor differences. Only glomerular filtration rates (*p*?=?0.011) and creatinine levels at 24 h (*p*?=?0.016) varied significantly between 50 g of AA and 75 g of AA (24 h post-infusion, 75 g vs. 50 g). Table [2](#T2){ref-type="table"} gives an overview of all biochemical parameters.

###### 

Biochemical parameters at baseline, 4 h and 24 h after the beginning of amino acid (AA) infusion

                       **Normal range**   **Baseline (75 g AA)**   **Baseline (50 g AA)**   ***p*value (baseline 75 g vs. 50 g AA)**   **4 h post-infusion (75 g AA)**   **4 h post-infusion (50 g AA)**   ***p*value (4 h post-infusion 75 g vs. 50 g AA)**   **24 h post-infusion (75 g AA)**   **24 h post-infusion (50 g AA)**   ***p*value (24 h post-infusion 75 g vs. 50 g AA)**
  -------------------- ------------------ ------------------------ ------------------------ ------------------------------------------ --------------------------------- --------------------------------- --------------------------------------------------- ---------------------------------- ---------------------------------- ----------------------------------------------------
  Potassium (mmol/l)   3.5-5              4.4?±?0.4                4.3?±?0.42               0.491                                      5.8?±?0.7                         5.7?±?0.8                         0.338                                               4.5?±?0.4                          4.6?±?0.4                          0.243
  GFR (ml/min)         \>60               89.5?±?27.1              89.4?±?24.6              0.862                                      85.3?±?24.8                       84.0?±?26.2                       0.324                                               84.6?±?26.2                        93.2?±?26.9                        *0.011*
  Creatinine (mg/dl)   \<0.95             0.89?±?0.27              0.85?±?0.28              0.444                                      0.92?±?0.24                       0.91?±?0.26                       0.952                                               0.93?±?0.25                        0.83?±?0.19                        *0.016*
  BUN (mg/dl)          10-50              33.28?±?12.86            30.91?±?14.16            0.808                                      41.88?±?12.23                     40.2?±?14.06                      0.872                                               35.62?±?13.81                      34.7?±?22.16                       0.099
  Phosphate (mmol/l)   0.87-1.45          1.08?±?0.19              1.06?±?0.17              0.601                                      0.85?±?0.16                       0.96?±?0.16                       0.167                                               1.16?±?0.25                        1.15?±?0.24                        0.074
  Chloride (mmol/l)    94-110             99.00?±?2.00             109.44?±?27.95           0.180                                      106.00?±?4.59                     109.13?±?2.29                     0.102                                               103.55?±?5.24                      107.15?±?2.67                      0.157
  LDH (U/l)            \<250              216.65?±?66.11           205.04?±?57.65           0.811                                      223.41?±?55.08                    257.18?±?128.22                   0.953                                               217.2?±?52.58                      247.69?±?82.70                     0.674

Values are means?±?SD. *GFR* glomerular filtration rate, *BUN* blood urea nitrogen, *LDH* lactate dehydrogenase, *mmol/l* millimoles per litre, *ml/min* millilitres per minute, *mg/dl* milligrams per decilitre, *U/l* units per litre. Values in italics denote significant difference.

Discussion
==========

This is the first intra-individual comparison of hyperkalaemia induced by 50 or 75 g of nephroprotective amino acids (Arg-Lys) in patients with neuroendocrine tumours undergoing PRRT. Incidence and severity of hyperkalaemia (\>5.0 mmol/l) were comparable for both protocols.

In PRRT, AA-induced hyperkalaemia is believed to result from the ketogenic characteristics of lysine, lowering intracellular pH and thereby causing an outwardly directed K^+^ flux \[[@B14]\]. Various publications have previously reported on AA-induced increase of serum potassium levels. For example, Barone and colleagues found just marginal increase in K^+^ levels in patients treated with a mixture of arginine and lysine totaling 50 g \[[@B11]\]. However, only six patients were included in this study and blood samples were drawn at an early time point (2.5 h after the start of infusion). Recently, a group from Switzerland reported on hyperkalaemia after administration of 25 g lysine and 25 g arginine. In their cohort, serum potassium levels increased significantly 4 h after the beginning of AA infusion \[[@B16]\]. Last, Rolleman et al. reported on even more pronounced K^+^ increases induced by 75 g of lysine, warning of AA-induced hyperkalaemia. In our cohort, we observed higher values of potassium than previously reported \[[@B13]\]. The reason for this observation is not fully understood. In order to rule out spurious hyperkalaemia, blood haemolysis indices were calculated. One possible explanation might be the pH value of the amino acid solution administered, which in our department is 7.0. Serum acidosis is known to be associated with potassium movement from the cellular space into the extracellular fluid in order to buffer excess hydrogen ions. The rather high volume infusion of 1,500 ml of AA might affect serum pH and thereby subsequently influence serum potassium. The total amount of AA solution administered did not influence incidence or severity of hyperkalaemia. Therefore, our data hint at a major contribution of the pH of the AA solution which was the same in all cycles.

Both infusion protocols were equally well tolerated. Most of the patients experienced asymptomatic rises in K^+^, and symptoms resolved quickly within 24 h without any further intervention. Three patients became symptomatic including palpitations, chest pain and general discomfort. Two of those three patients suffered from hyperkalaemia-related side effects regardless of the amount of AA infused, whereas the remaining subject only experienced discomfort with 75 g of AA. Interestingly, this subject had lower K^+^ values after administration of 50 g AA (6.1 mmol/l) as compared to 75 g AA (7.0 mmol/l). In all, treatment with insulin and glucose was highly effective and symptoms were relieved quickly.

Changes in other serum parameters included a non-significant decrease in phosphate, increase in BUN or changes in chloride which were also not significant, consistent with studies published before \[[@B16]\]. Also, no significant changes in kidney function were observed. According to our study, only a transient increase of serum creatinine after start of the AA infusion has been reported \[[@B11]\] and might be associated with higher doses of AA due to non-specific tubular cell blockade. Resolution was observed after 24 h. In short, hyperkalaemia as an adverse event to a potentially life-threatening degree has to be kept in mind regardless of the AA protocol used for PRRT.

The following limitations have to be considered: firstly, the retrospective study design and the low patient number may be associated with a significant sample bias. Secondly, this study does not allow any conclusions regarding the nephroprotective effect of the different AA amounts. Therefore, future prospective studies with larger patient numbers need to be performed, potentially also investigating the long-term effectiveness and safety of AA co-infusion protocols with even lower AA amounts. However, to the best of our knowledge, this is the first report on an intra-individual comparison of two different AA protocols.

Conclusions
===========

Transient hyperkalaemia is a frequent side effect of AA co-infusion during PRRT. In contrast to previous reports, incidence and severity of hyperkalaemia do not significantly vary between different amounts of AA administered.
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